TheraCryf (LON: TCF) says clinical trial enabling work for the Ox-1 blocker for treating substance use disorders is ahead of plan. Manufacturing has been scaled up, and dosing is complete in the rodent toxicology study. The remaining activities should be completed in the third quarter enabling the move to a phase 1 study in human volunteers. An application for a phase 1 clinical trial is expected to be submitted this year. The share price increased 15.9% to 0.255p.
Recruitment firm Gattaca (LON: GATC) has sparked an upgrade with its latest trading statement, which suggests that it is outperforming its rivals. Contract recruitment is doing better than expected and cost have been kept under control. Defence, energy and infrastructure sectors have been strong. Panmure Liberum has raised its 2025-26 pre-tax profit forecast by one-third to £6m. The share price gained 14.3% to 124p.
OptiBiotix Health (LON: OPTI) plans to demonstrate its SweetBiotix product to shareholders in June. It will also update them on the progress of other products. The share price rose 14% to 5.7p.
Video surveillance technology developer Thruvision (LON: THRU) has added RedteQ in the UK and Bavak Security in the Netherlands to its value added reseller network. This will provide additional impetus to sales. The share price improved 3.23% to 0.8p.
FALLERS
First quarter results from Touchstone Exploration (LON: TXP) show average production of 4,657boe/day. Production was slightly higher in April and commissioning of the Cascudura compressor will further increase the rate. There also two new wells set to come onstream. Quarterly revenues were 14% higher at $12.5m. Net debt was $76.1m at the end of March 2026. Pricing for gas sales in Trinidad is fixed until October 2027. Oil sales benefit from the current higher price. The share price slumped 22.6% to 0.6p.
Telematics company Microlise (LON: SAAS) is focusing on direct business as renewals from OEMs are suffering pressure on pricing and the loss of contracts. Direct annualised recurring revenues were 16% higher, despite delays to some contracts, but this was partly offset by a 13% reduction in the OEM figure. Pre-tax profit slumped from £6.5m to £2.6m. Net cash increased to £16.7m. Capital investment will be sharply higher in 2026 and 2027 and that will use up some of the cash. The final dividend was raised from 1.24p/share to 1.3p/share. The share price slid 15.5% to 49p.
Trading conditions have got worse for meat and agricultural products producer Zambeef (LON: ZAM) with 2025-26 revenues expected to be one-fifth below market expectations. Trading has been poor since the start of the Middle East conflict and fertiliser prices have increased, although Zambeef has enough fertiliser until September. Revenues are still expected to improve from $302.6m to $323.9m, while pre-tax profit should recover from $9.5m to $12.1m. The higher fertiliser prices could hit next year, and pre-tax profit is currently expected to decline to $10.3m. The share price declined 6.86% to 4.75p.
Tap Global Group (LON: TAP) is offering Tap Earn to eligible customers in the UK. This offers a yield of up to 7% on supported stablecoin holdings, up to 3.5% on Ethereum and up to 2.5% on Bitcoin. Tap Earn is available across all the company’s markets. The share price fell 4% to 1.2p.
Ex-dividends
FRP Advisory (LON: FRP) is paying a dividend of 1p/share and the share price dipped 0.5p to 113.5p.
Tracsis (LON: TRCS) is paying an interim dividend of 1.3p/share and the share price is unchanged at 355p.